本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2013/6/41 分钟阅读
Eli Lilly and Co.; Withdrawal of Approval of a New Drug Application for ORAFLEX
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) for ORAFLEX (benoxaprofen) Tablets, held by Eli Lilly and Co. (Lilly), Lilly Corporate Center, Indianapolis, IN 46285. Lilly has voluntarily requested that approval of this application be withdrawn, and has waived its opportunity for a hearing.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →